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OBJECTIVE — To assess the risk factors for the presence and severity of obstructive sleep
apnea (OSA) among obese patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS — Unattended polysomnography was per-
formed in 306 participants.
RESULTS — Over 86% of participants had OSA with an apnea-hypopnea index (AHI) 5
events/h. The mean AHI was 20.5  16.8 events/h. A total of 30.5% of the participants had
moderate OSA (15  AHI 30), and 22.6% had severe OSA (AHI 30). Waist circumference
(odds ratio 1.1; 95% CI 1.0–1.1; P  0.03) was signiﬁcantly related to the presence of OSA.
Severe OSA was most likely in individuals with a higher BMI (odds ratio 1.1; 95% CI 1.0–1.2;
P  0.03).
CONCLUSIONS — Physicians should be particularly cognizant of the likelihood of OSA in
obese patients with type 2 diabetes, especially among individuals with higher waist circumfer-
ence and BMI.
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W
e report the prevalence of ob-
structive sleep apnea (OSA) and
the factors that increase the risk
and severity of OSA among 306 obese pa-
tients with type 2 diabetes enrolled in
Sleep AHEAD, a four-site ancillary study
of the Look AHEAD Trial (Action for
Health in Diabetes).
RESEARCH DESIGN AND
METHODS— Look AHEAD (1,2) is a
16-centertrialinvestigatingthelong-term
health impact of an intensive lifestyle in-
tervention in 5,145 overweight and obese
adultswithtype2diabetes.Exclusioncri-
teria for Sleep AHEAD were previous
treatment for OSA.
The protocol was approved by each
site’s Institutional Review Board. Partici-
pants interested in Sleep AHEAD were
consented at a Look AHEAD screening
visit. Efforts were made to enroll individ-
uals with undiagnosed OSA using a
symptom questionnaire (3). Because al-
most all of the ﬁrst 80 participants had
OSA upon polysomnography, the symp-
tom screen was dropped as an eligibility
criteria.
Polysomnography
A home unattended overnight polysom-
nogram (Compumedics, Abbotsville,
Australia) was performed using tech-
niques developed for the Sleep Heart
HealthStudyexceptthatairﬂowwasmea-
sured by nasal pressure cannula and oro-
nasal thermistor (4). Polysomnograms
were scored using recommended criteria
(5). Hypopneas had to be associated with
a 4% oxygen desaturation (5). The
overall failure rate for the home polysom-
nography recordings was 8%; 90%
were due to equipment breakdown.
Weight, height, waist (2), and neck
(6) circumferences and the Epworth
Sleepiness Scale (7) were assessed within
1 week of the polysomnogram without
knowledge of its results.
Statistical analysis
Participants were categorized by apnea-
hypopnea index (AHI) into mild (5–
14.9), moderate (15–29.9), and severe
(30) OSA. Group differences were as-
sessed using 
2 and t tests. Variables that
were correlated with AHI were included
in logistic regressions to predict the pres-
ence of OSA (AHI 5) and, after remov-
ing participants with no OSA (n  40),
severity of OSA. The same variables were
used to predict AHI as a continuous (log-
transformed) variable. Interactions were
included to assess sex differences. Re-
search site was included in all models.
RESULTS
Participant characteristics
One participant with central sleep apnea
was removed from all analyses. Partici-
pant characteristics are in Table 1. A total
of60%werewomen.Ofthefemales,90%
were postmenopausal. Nearly three-
quarters (72.0%) had dyslipidemia,
82.6% had hypertension, and 93.4% had
the metabolic syndrome.
There were no differences between
individuals who were enrolled in Sleep
AHEAD (n  305) and those enrolled in
Look AHEAD but not in Sleep AHEAD at
thefourSleepAHEADsites(n1,012)in
weight, BMI, sex, race/ethnicity, or waist
circumference. Sleep AHEAD partici-
pants were slightly older (61.3  6.5 vs.
58.7  6.9 years; P  0.0001) and had
lower A1C values (7.2  1.1 vs. 7.4 
1.2%; P  0.03) than Look AHEAD par-
ticipants who were not enrolled in Sleep
AHEAD. There were small but signiﬁcant
differences in the frequency of snoring
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AHEAD, P  0.01) (1  do not snore
anymore, to 4  6–7 nights per week)
and in those already diagnosed with OSA
(7.6% Sleep AHEAD; 13.4% Look
AHEAD, P  0.01). There were no differ-
ences in the presence or loudness of snor-
ing or excessive daytime sleepiness. No
symptoms assessed in this study pre-
dicted the presence or severity of OSA.
Sleep-disordered breathing
Only 13.4% of participants did not have
OSA, whereas 33.4% had mild OSA,
30.5% moderate OSA, and 22.6% severe
OSA. Similar ﬁndings were obtained in
participants who did not have a previous
diagnosis of OSA and had not been pre-
screened based on symptoms (n  202).
Males had a higher AHI than females.
BMI, sex, and waist and neck circumfer-
ence were related to AHI. Waist circum-
ference was the only signiﬁcant predictor
(odds ratio [OR] 1.1; 95% CI 1.0–1.1;
P  0.03) of the presence of OSA (AHI
5). Independent of other variables, a
1-cm increase in waist circumference was
associated with a 10% increase in the
predicted odds of the presence of OSA
(AHI 5).
In participants with AHI 5( n 
264),BMIwastheonlysigniﬁcantpredic-
tor of severe OSA (OR 1.1; 95% CI 1.0–
1.2; P  0.03). Independent of other
variables, a 1-unit increase in BMI was
associatedwitha10%increaseinthepre-
dicted odds of severe OSA. Sex ap-
proached signiﬁcance. Males were 2.2
timesmorelikelytohavesevereOSAthan
females (OR 2.2; 95% CI 0.9–5.3; P 
0.08). In the full sample (n  305), waist
circumference was the only statistically
signiﬁcant predictor of continuous AHI
(0.02,95%CI0.01–0.03;P0.04).
None of the interaction terms was statis-
tically signiﬁcant.
CONCLUSIONS— The most re-
markable ﬁnding of this study is the ex-
ceedingly high prevalence of
undiagnosed OSA (86.6%) among obese
patients with type 2 diabetes. These data
were suggested by earlier studies of
smallersamplesand/orthatusedlessthan
full polysomnography to assess AHI (8–
10). Equally alarming is the unequivo-
cally elevated mean AHI (20.5  16.8) of
this group and that 22.6% of participants
had severe OSA. Even though obesity,
age, and menopause are known risk fac-
tors for OSA (11–13), the extraordinarily
highratesofundiagnosedandsevereOSA
in this cohort are remarkable. Given the
similarities between the participants in
Sleep AHEAD versus Look AHEAD (but
not in Sleep AHEAD), our results do not
appeartobesecondarytoaselectionbias.
Potential links between OSA and type 2
diabetes have been recently reviewed
(14). Deﬁnitive conclusions about the
prevalence of OSA among individuals
with type 2 diabetes require a control
group without diabetes.
The second major ﬁnding was that
waist circumference was the only signiﬁ-
cant predictor of the presence of OSA
(AHI 5) (15). The failure of neck cir-
cumference and BMI to contribute to the
Table 1—Sleep AHEAD participant characteristics at baseline
Total Sleep AHEAD
participants
Sleep AHEAD
participants (male)
Sleep AHEAD
participants (female) P
n 305 122 183
Race/ethnicity (%) 0.0001
White 73.0 90.1 61.8
African American 19.1 6.6 27.3
Other 7.9 3.3 10.9
Postmenopause 90.1 N/A 90.1 n/a
Age (years) 61.3  6.5 61.4  7.1 61.3  6.1 0.89
BMI (kg/m
2) 36.5  5.8 36.1  5.6 36.7  5.9 0.34
Weight (kg) 101.7  18.0 110.9  16.5 95.6  16.2 0.0001
Height (cm) 167.0  9.7 175.5  7.0 161.3  6.6 0.0001
Waist circumference (cm) 115.0  13.0 120.9  12.1 111.0  12.1 0.0001
Neck circumference (cm) 41.1  4.4 44.4  3.2 39.0  3.1 0.0001
A1C 7.2  1.1 7.4  1.1 7.1  1.0 0.03
Total sleep time (h) 6.0  1.2 5.8  1.3 6.1  1.1 0.03
Sleep efﬁciency (%) 77.5  11.1 77.1  11.8 77.7  10.6 0.69
Time in non-REM stages (h) 4.9  1.0 4.9  1.1 5.0  1.0 0.32
Time in REM stages (h) 1.0  0.5 0.9  0.5 1.1  0.5 0.002
Sleep time supine (h) 2.1  2.0 1.9  1.9 2.2  2.1 0.21
Obstructive apnea index 11.1  12.8 14.2  15.5 9.1  10.2 0.008
Central apnea index 0.4  1.0 0.6  1.2 0.3  0.7 0.003
Hypopneas with 4% oxygen desaturation*
Apnea-hypopnea index 20.5  16.8 24.6  18.6 17.8  15.0 0.001
Hypopnea index 9.0  8.1 9.8  8.3 8.4  8.0 0.16
Oxygen desaturation index (4%)† 17.6  14.7 20.0  15.9 15.9  13.7 0.03
Participants that spent 10% of time below
90% saturation (%)
16.1 20.5 13.1 0.11
Oxygen saturation nadir 81.4  8.3 81.2  7.5 81.6  8.8 0.65
Epworth Sleepiness Score 7.9  4.6 8.0  4.5 7.8  4.7 0.80
Data are means  SD. *See Ref. 5. †Based on oxygen desaturation events 4% (5). REM, rapid eye movement.
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range of these variables in this sample
compared with a community sample.
Having a higher BMI, however, did in-
crease the risk of severe OSA (AHI 30).
CONCLUSIONS — Physicians treat-
ing obese patients with type 2 diabetes
should consider the possibility of OSA,
even in the absence of symptoms, espe-
cially in individuals with higher waist cir-
cumference and BMI. The high
prevalence of OSA in obese patients with
type2diabetesrepresentsaseriouspublic
health problem and raises the possibility
that some of the morbidity and mortality
associated with type 2 diabetes may be
attributable to undiagnosed OSA.
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